NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback